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The conﬂicts in Iraq and Afghanistan have placed an increased awareness on traumatic
brain injury (TBI).Various publications have estimated the incidence ofTBI for our deployed
servicemen, however all have been based on extrapolations of data sets or subjective eval-
uations due to our current method of diagnosing aTBI.Therefore it has been difﬁcult to get
an accurate rate and severity of deployment relatedTBIs, or the incidence of multipleTBIs
our service members are experiencing. As such, there is a critical need to develop a rapid
objective method to diagnoseTBI on the battleﬁeld. Because of the austere environment
of the combat theater the ideal diagnostic platform faces numerous logistical constraints
not encountered in civilian trauma centers. Consequently, a simple blood test to diagnosis
TBI represents a viable option for the military.This perspective will provide information on
some of the current options for TBI biomarkers, detail concerning battleﬁeld constraints,
and a possible acquisition strategy for the military.The end result is a non-invasiveTBI diag-
nostic platform capable of providing much needed advances in objective triage capabilities
and improved clinical management of in-TheaterTBI.
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THE TBI PROBLEM
In the early years of the wars inAfghanistan (Operation Enduring
Freedom, OEF) and Iraq (Operation Iraqi Freedom, OIF), there
appearedtobeanincreaseinthenumbersof causalitiessustaining
atraumaticbraininjury(TBI).Byearly2005TBIwasbeingcalled
the“signature wound of war in Iraq”as cases of soldiers suffering
from TBI were appearing in National newspapers, such as USA
Today (Okie, 2005; Zoroya, 2005). The increased awareness and
emphasis of TBI in the military population spurned a movement
toidentifyandcollectdataontheincidenceofTBIinourdeployed
forces.
The incidence of TBI in the deployed forces varies depending
uponthetypeofinformationcollected.Oneinitialstudyexamined
a cohort of casualties that were wounded in OEF/OIF from 2001
to 2005. The study reported that approximately 30% of wounds
were to the head and neck area with 8% of the total attributed
as head wounds (Owens et al., 2008). However, this study was
based on casualties treated for wounds, and excluded those that
were returned to duty within 72h, thus potentially missing TBI
cases that were mild and did not accompany an open wound. The
RAND Corporation’s “Invisible Wounds of War” collected data
from April 2007 to January 2008, part of which included a tele-
phone survey of 1,965 previously deployed persons. From this
survey they reported that 19.5% of the previously deployed per-
sonssufferedfroma“probableTBI.”Theyfurtherestimatedthatof
the1.64milliondeployedservicemembers(atthattime),19.5%of
them,or320,000havesufferedaTBI(TanielianandJaycox,2008).
However, data collected from the Armed Forces Health Surveil-
lance Center show that by the end of 2008 there had only been
approximately 130,000 clinically conﬁrmed cases of TBI. In addi-
tion, the number of TBI diagnosis rose sharply between the years
of 2005 thru 2009, speciﬁcally in the cases of mild TBI (mTBI;
http://www.health.mil/Research/TBI_Numbers.aspx). Is this rise
in TBI a real rise, or an increase in TBI awareness and improved
vigilance for detecting TBI? Clearly there appears to be a real chal-
lenge on getting an accurate estimate of the actual incidence of
TBI experienced by our deployed Forces.
DIAGNOSING TBI
One of the issues creating this challenge lies in the current lim-
itations in the diagnosis of TBI, speciﬁcally for the military. In
general, the diagnosis of TBI relies on a clinician to accurately
interpret a patient’s signs and symptoms of injury, often through
some type of self-report from the patient and possibly corrob-
orated by a witness. In the case of a penetrating brain injury,
the signs and symptoms are more straightforward. However,with
closed-headinjuries,especiallymTBIs/concussions,thesymptoms
are often not as straightforward or clear. Typically the initial eval-
uationof apossibleTBIcapturesthepatientsGlasgowComaScale
(GCS),thelengthof lossof consciousness,alterationof conscious-
ness/mental state, and/or post-traumatic amnesia (Harrington
etal.,1993;Meyeretal.,2010).If certainsymptomsarepresentthe
clinician can further evaluate the injury by image analysis of the
brainviaacomputedtomography(CT)scanorevenmagneticres-
onance imaging (MRI), both of which have their own limitations
in the ability to detect TBI,especially mTBI (Chastain et al.,2009;
Mondello et al., 2011a; Prabhu, 2011). Besides the image analysis,
most of the tools to aid in the diagnosis of TBI are subjective and
as stated above involve self-reporting. Hence, there are no true
objective measures available to determine that the brain indeed
has been injured, thus the ability to diagnose closed-head TBI,
especiallythoseof themild-moderateseverity,isatbestlimitedby
www.frontiersin.org June 2012 | Volume 3 | Article 90 | 1Schmid andTortella TBI diagnosis on the battleﬁeld
availablemethods.However,theabilitytodiagnosisaTBIcanalso
be limited by the setting.
The civilian environment and the military (deployed) envi-
ronment are vastly different. In a civilian setting, if someone
experiences a head injury from a motor vehicle accident, fall, or a
sportingevent,theeventisoftenwitnessed;theyarequicklytrans-
ported to the local medical facility and promptly evaluated by a
medical professional, sometimes with access to the latest imaging
technology.Inthemilitarysetting,thereisoftensometypeofbattle
taking place either before,during, or after,when someone experi-
ences a head injury. By its very nature the event is dangerous, and
oftenchaoticandloud,occurringinremotelocationsandpossibly
lasting hours before casualties can be evaluated by a clinician. In
addition, the military casualty can and often will experience mul-
tipleseriousinjuries(Kellyetal.,2008;Owensetal.,2008)andthe
evaluation of a potential head injury can take a back seat to life
saving interventions, possibly missing the treatment window for
the TBI. Further, evacuation priorities and logistics may impact
the ability to evaluate all suspected mTBI cases to the same extent
as a civilian setting as the ability to image the brain is only located
at speciﬁc locations in the theater of operations. Clearly the mil-
itary setting creates another layer of difﬁculty and complexity in
the ability to diagnose TBI.
ON THE BATTLEFIELD
Due to the complexities of war and of TBI, it has been extremely
difﬁcult to get a handle on the rate of TBIs experienced during a
deployment, not to mention the severity of TBIs or the incidence
of multipleTBIsourservicemembersareactuallyexperiencing,or
notexperiencing.Oneof themajorreasonsisthelackof amethod
to objectively determine if the brain has been injured. In 2006 the
MilitaryAcute Concussion Evaluation (MACE) was add to the list
of tools to screen casualties (Meyer et al.,2010). While the MACE
has been well integrated into the military medical evaluation, it
still relies on subjective recall of the events, may be affected by
fatigueasotherneuropsychologicaltestsandhasshownlowsensi-
tivity when administered greater than 12h (Coldren et al., 2010).
Thus there remains a gap for the ability to objectively measure
brain injury with a method that is not impacted by other factors
such as extra-cranial injury (i.e., polytrauma), stress, fatigue, or
battleﬁeld conditions.
Due to the logistic constraints faced on a battle ﬁeld, any
method involving a piece of equipment, must meet additional
requirements sometimes not faced in civilian medical care. The
battleﬁeld is often a very austere environment. The most restric-
tiveenvironmentsareoftenisolatedlocationswherepowersupply
is lacking or being provided by a generator which must sustain
all of the electrical needs for the deployed force. Since units often
needtoremainquicklymobile,thefootprintof theunitislimited,
so space, and weight of equipment is a priority concern. In addi-
tion,if medical refrigeration exists,it is typically small and in high
demandandthereislittlehopeof havingspecializedreagentssuch
as deionized water. Further consideration is given to the shelf-life
of a piece of equipment and its ability to sustain high altitude,
large temperature, and/or humidity ﬂuctuations and a consider-
ably dusty and dirty environment. Taking all of these issues into
consideration,the ideal method for the diagnosis of TBI would be
quick,simple,easy to obtain,not rely on self-report of symptoms,
and be portable. In addition, the results of the test should be able
to differentiate the severity of injury and in a most ideal world,be
predictive of some level of clinical outcome.
OBJECTIVE DIAGNOSTIC TEST FOR TBI
In recent years there have been a number of technologies under
development to objectively aid in the diagnosis of TBI (Marion
etal.,2011).Someof theseincludeadvancesinMRI(Kumaretal.,
2010; Prabhu, 2011), quantitative electroencephalogram (EEG;
Nuwer et al., 2005), visual tracking (Maruta et al., 2010), and
serum based biomarkers of brain injury (Dash et al.,2010). Using
thelogisticalconstraintsmentionedaboveandtheneedforthetest
tonotbeconfoundedbyconditionsof deployment(sleepdepriva-
tion,stress,fatigue,etc.),one of the more promising options is the
developmentofasimplebloodtesttodetectbrainspeciﬁcproteins
afteraTBI.Bloodbasedtestshavebeensuccessfulinthediagnosis
of other disease conditions such as cardiac disease and cancer, so
it is possible biomarkers could be identiﬁed for TBI as well.
The TBI community has been actively engaged in the discov-
ery of biomarkers for TBI in the last decade. A number of review
articleshavecapturedtheprosandconsofvariouspotentialmark-
ers (Dash et al., 2010; Mondello et al., 2011a). Some of the more
promising candidates have been tested in human clinical trials of
TBI patients, most of them in severe TBI (Hergenroeder et al.,
2010; Liliang et al., 2010; Mondello et al., 2010, 2011b, 2012a,b;
Vos et al., 2010; Brophy et al., 2011; Stein et al., 2011, 2012; Gong
et al.,2012). A number of proteins of interest are markers that are
not solely found in the brain (i.e.,cytokines,growth factors,inter-
leukins; Hergenroeder et al., 2010; Stein et al., 2011; Gong et al.,
2012).Whilethesemayprovideclinicalutilityinsituationsofhead
trauma with no confounding injuries,this is typically not the case
in the military combat causality. However, a number of markers
of interestaremorebrainspeciﬁc,toincludeS100B,glialﬁbrillary
acidicprotein(GFAP),UbiquitinC-terminalhydrolaseL1(UCH-
L1),NeuronSpeciﬁcEnolase(NSE),spectrinbreakdownproducts
(SBDP),andTau(Simanetal.,2009;Liliangetal.,2010;Mondello
et al., 2010, 2011b, 2012a,b; Vos et al., 2010; Brophy et al., 2011;
Stein et al., 2012).
Most of the clinical trials have been conducted with severe
TBI patients, but a few have also included moderate and mTBI
patients as well and show promise (Honda et al.,2010; Papa et al.,
2012a,b;Topolovec-Vranicetal.,2011;Egea-Guerreroetal.,2012).
In an early study of S100B in mTBI subjects, S100B serum levels
were signiﬁcantly different between mTBI patients and uninjured
controls (Nygren De Boussard et al., 2004). However, S100B is
also increased in other extra-cranial injuries, making less than
ideal in the military environment (Savola et al., 2004). Promis-
ingrecentstudiesincludeastudyonmoderate-mTBI(GCS12),
that demonstrated that the levels of GFAP in patient serum were
able to signiﬁcantly differentiate not only between TBI patients
anduninjuredcontrols,butalsobetweenTBIpatientsandtrauma
controls (trauma injury without head injury). Further, when TBI
groups were dichotomized into traditional groups of mTBI (GCS
13–15) and moderate TBI (GCS 9–12), the level of serum GFAP
were signiﬁcantly different between groups (Papa et al., 2012a).
Similar results were demonstrated with serum levels of UCH-L1
differentiatingbetweenmTBI,moderateTBI,normal,andtrauma
controls (Papa et al.,2012b).Another study recently characterized
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the differences in areas under the curve (AUC) for sensitivity and
speciﬁcity of GFAP, S100B, and NSE in TBI patients (GCS range
5–14) determined by positive CT ﬁndings. GFAP performed the
best with sensitivity set to 100% and the corresponding speciﬁcity
was 88.9% on day one compared to S100B with a speciﬁcity of
27.8% and NSE with a speciﬁcity of 22.2% on day one (Honda
et al., 2010).
TBI BIOMARKER PLATFORMS FOR THE FIELD
Although recent trials have indicated that it is possible to detect
TBI biomarkers in the serum of injured patients,all of the studies
have taken place in civilian centers and were able to use a research
laboratory platform for analysis. Typically this platform is a stan-
dard enzyme-linked immunosorbent assay (ELISA) which has a
number of limitations for use in a combat environment. First,the
typical assay requires multiple pieces of equipment (reader, incu-
bator,andautomatedwashingmachine),refrigerationof reagents,
and deionized water. Second, the assay can be lengthy to run, tak-
ing as little as 4h and as many as 24h. Third, the standard assay
plateconsistsof96wells,whichcouldequatetowastingtwo-thirds
of a plate if there is only one sample to assay. However, when we
consider the needs for our military applications the assay in an
ELISA platform is indeed the most mature in development and
testing of clinical samples. Similarly this platform could poten-
tially have greater sensitivity (lower limits of detection) and serve
as a benchtop in a reference laboratory. In addition, porting the
standardELISAassayontoanautomatedbenchtopplatformcould
cut down on some of the size and weight of the system.
On the other end of the spectrum would be the development
of a hand-held device that performs similar to a TBI “pregnancy
test.”Such hand-held systems would be lightweight,portable,and
require little logistical support. The assay time and waste would
likely be reduced as well. However, these devices do not exist
today for the TBI biomarkers that have been examined in clin-
ical studies; therefore they are the least mature in development
and Food and Drug Administration (FDA) approval timeline. In
addition, it is possible that this platform could suffer in the limit
of detection.
As mentioned above,the development of a device platform for
the military environment presents unique challenges with differ-
ent restrictions upon instrumentation at each level of care. The
initial level of combat casualty care is located close to the point of
injurysuchasaBattalionAidStation(BAS).Thislevelofcareisthe
most remote and has the highest logistical constraints concerning
power, refrigeration, and footprint. In addition, this level of care
does not have much capacity,if any,to hold patients for treatment
and evaluation. The most robust level of care on the battleﬁeld
is located at a combat support hospital (CSH) or a ﬁeld hospital.
It includes specialist diagnostic resources, specialist surgical and
medical capabilities, and operational stress management teams.
The holding capacity is sufﬁcient to allow diagnosis, treatment,
and holding of those patients who can receive total treatment and
be returned to duty. However, it is still a deployed environment
faced with the same challenges of reduced and restricted foot-
print, especially for power and refrigeration. For the highest level
of deﬁnitive care,patients are evacuated back to ﬁxed facility hos-
pitals such as Landstuhl Regional Medical Center or Walter Reed
National Military Medical Center. These hospitals operate as any
civilian medical facility with few, if any, logistical constraints.
MILITARY ACQUISITION APPROACH
Given (1) the importance of providing an objective test to aid in
the diagnose of TBI,(2) the level of maturity of platforms to eval-
uate TBI biomarkers, and (3) the unique abilities and constraints
on each level of possible medical care, the best approach to solve
this problem may be an phased acquisition approach (Mondello
et al., 2011a; Figure 1). The ﬁrst phase of development/ﬁelding
shouldfocusonthetechnologythatisthemostmature,andpoten-
tially ﬁeldable, not only in terms of platform logistics but also in
clinical testing and familiarity with the FDA. Therefore, Phase I
could focus on an automated benchtop system suitable for use in
a ﬁxed medical facility. Although this system is the most complex
and logistically intensive, it is the most similar to the standard
research ELISA that have been employed in previous testing of
clinical samples. In addition, it could possibly have the highest
levelof sensitivityfordetectionof biomarkersandultimatelyserve
as a reference platform for conﬁrmatory testing (higher diagnos-
tic speciﬁcity). Phase II could be a small single assay point-of-care
system, such as a physician’s ofﬁce or a ﬁeld hospital. Phase II sys-
tems would ideally have the ability to screen for the presence of
mild-moderate TBI and differentiate the level of severity for all
TBIs. Ideally Phase II systems would be more portable than Phase
Isystems,havetheavailabilityof batteryoperationandrequireless
refrigeration of reagents. Phase III systems could be a miniatur-
izedhand-heldsystem,mostsuitableforusebyemergencymedical
personnel or personnel deployed in the remote and more austere
locations on the battleﬁeld, such as a BAS. These systems would
ideally use whole blood from a ﬁnger stick to screen for the pres-
ence of TBI. They would use little power supply and require no
refrigeration. Currently, Phase III systems are the least mature
in development and testing for TBI biomarkers, but would pro-
vide the most use for screening of casualties (highest diagnostic
sensitivity).
If allthreePhasesof systemsweredevelopedanddeployed,one
could image a scenario that starts with screening casualties for the
presence of TBI biomarkers immediately after an event. Screening
tests can typically have higher diagnostic sensitivity than diag-
nostic speciﬁcity (Ruan et al., 2009; i.e., more false positives than
falsenegatives).Usingascreeningtestdesignedinthismannerwill
ensureyoudonotmissacasualtywithapossibleTBI,howeveryou
willhavemorepeopleidentiﬁedashavingaTBIthatcouldlaterbe
ruledout.Thecasualtycouldbeevacuatedbacktothenexthigher
level of care that can provide a more robust conﬁrmatory test for
the TBI biomarkers. At the highest level of care, the test could be
more conﬁrmatory and have a higher diagnostic speciﬁcity than
sensitivity (lower number of false positive) and essentially rule in
those with TBI and determine which casualties were false posi-
tives for the screening test. In addition, TBI biomarker assays at
the highest level of care could also be used to possibly determine
what type of injury has occurred and monitor if the injury is get-
ting worse over time or better with treatment (Mondello et al.,
2011a). This scenario also ﬁts well with the current military lev-
els of medical care on the battleﬁeld. The biomarker assay screen
(Phase I/II) could be completedduring the initial assessment after
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FIGURE 1 | Potential placement ofTBI diagnostic assay systems. Each
potential device has advantages and disadvantages that constrain its use
in the military medical system. Solid lines represent ideal placement of
each system, dashed lines represent possible placement of each system
depending on logistical support. All device pictures are representative
examples of commercially available devices, but do not indicate the use of
TBI biomarkers on each device. Pictured benchtop device is Dynex
Technologies DS2™and DSX™(http://www.dynextechnologies.com),
pictured point-of-care device is Abbott Laboratories ISTAT
®
(http://www.abbottpointofcare.com).
injury,wheretheotherscreeningtest,theMACEisperformed.The
biomarker assay conﬁrmatory test (Phase III) could be performed
at a ﬁeld hospital where other more extensive diagnostic tools are
available, such as a CT.
SUMMARY
OverallthecurrentmethodstodiagnosisaTBIcouldbeimproved
with the development and addition of a non-invasive, objec-
tive test for the presence of TBI. Current research and develop-
ment in the ﬁeld of biomarkers give hope the development of
such an objective diagnostic test. However, military conditions
contain logistical constraints which may require different plat-
formsfordifferentlevelsofcare.Developmentofthisnon-invasive
TBI diagnostic platform applicable to all levels of military care
would provide much needed advances in objective triage capa-
bilities and improved clinical management of in-Theater TBI.
The ability to objectively determine the occurrence of an ini-
tial mTBI/concussion and the incidence of multiple mTBIs on
our front lines of defense is critical to the success of our military
operations, and to the long term health of our warﬁghters. Like-
wise, improved TBI diagnosis will also signiﬁcantly advance the
management of civilian patients.
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